Kneu Health Deepens U.S. Push With TMC Innovation Graduation and Flagship Health System Deployments

New updates have been reported about Kneu Health.

Kneu Health is accelerating its U.S. expansion after completing the Global Incubator program at Texas Medical Center Innovation in Houston, gaining direct access to clinical leaders and health systems in the world’s largest medical complex. The company’s smartphone-based neurology platform, built on a decade of Oxford research, provides daily assessments of movement, speech and cognition to generate continuous clinical insights for Parkinson’s and dementia care.

The TMCi engagement coincides with growing commercial traction, including a six-month deployment with Cedars-Sinai’s Division of Movement Disorders, where continuous monitoring informed earlier intervention in 79% of clinical encounters. Kneu is also rolling out its technology with Mass General Brigham, supported by a $5.6 million seed round co-led by Oxford Science Enterprises and Cedars-Sinai and by U.S. FDA clearance of its phone-only Parkinson’s tremor module, which removes the need for dedicated hardware.

These milestones position Kneu to scale across major U.S. health systems as neurological disease prevalence rises and payers push for more proactive, data-driven care models. CEO and co-founder Caroline Cake said that working within the Texas Medical Center ecosystem is helping validate how continuous neurological data can reshape decision-making compared with traditional episodic visits.

Kneu’s momentum is also being showcased on the innovation circuit: the company won the inaugural SXSW London Venture Spotlight, securing a £100,000 award, and will present at SXSW in Austin from March 12–16. For executives and investors, the combination of prestigious health-system deployments, regulatory clearance, institutional backing and high-visibility recognition signals that Kneu is moving from research validation into scaled commercialization in the U.S. neurology market.